Name: UMIN ID:
Unique ID issued by UMIN | UMIN000024676 |
---|---|
Receipt number | R000028387 |
Scientific Title | A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: J-SUPPORT 1604 |
Date of disclosure of the study information | 2016/11/01 |
Last modified on | 2019/05/04 13:08:34 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/11/01 21:52:05 | ||
2 | Update | 2017/03/19 15:08:04 | Recruitment status Anticipated trial start date |
|
3 | Update | 2017/05/31 09:38:30 | Email1 Email2 |
|
4 | Update | 2018/11/05 14:04:26 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete |
|
5 | Update | 2019/04/09 17:13:23 | Date of IRB Date analysis concluded |
|
6 | Update | 2019/04/09 17:18:34 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
7 | Update | 2019/05/04 13:08:34 | Recruitment status |